XML 15 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Total Caladrius Biosciences, Inc. Stockholders' Equity
Series B Convertible Preferred Stock
Common Stock
Additional Paid in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Non- Controlling Interest in Subsidiary
Beginning Balance (shares) at Dec. 31, 2019     10 10,529          
Beginning Balance at Dec. 31, 2019 $ 20,553 $ 20,816 $ 0 $ 11 $ 438,911 $ 2 $ (417,400) $ (708) $ (263)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net (loss) income 2,616 2,608         2,608   8
Unrealized loss on marketable securities (9) (9)       (9)      
Share-based compensation (in shares)       106          
Share-based compensation 713 713     713        
Net proceeds from issuance of common stock and warrants (in shares)       4,950          
Net proceeds from issuances of common stock and warrants 9,683 9,683   $ 5 9,678        
Ending Balance (shares) at Jun. 30, 2020     10 15,585          
Ending Balance at Jun. 30, 2020 33,556 33,811 $ 0 $ 16 449,302 (7) (414,792) (708) (255)
Beginning Balance (shares) at Mar. 31, 2020     10 10,639          
Beginning Balance at Mar. 31, 2020 16,984 17,243 $ 0 $ 11 439,330 0 (421,390) (708) (259)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net (loss) income 6,602 6,598         6,598   4
Unrealized loss on marketable securities (7) (7)       (7)      
Share-based compensation (in shares)       (4)          
Share-based compensation 294 294     294        
Net proceeds from issuance of common stock and warrants (in shares)       4,950          
Net proceeds from issuances of common stock and warrants 9,683 9,683   $ 5 9,678        
Ending Balance (shares) at Jun. 30, 2020     10 15,585          
Ending Balance at Jun. 30, 2020 33,556 33,811 $ 0 $ 16 449,302 (7) (414,792) (708) (255)
Beginning Balance (shares) at Dec. 31, 2020     10 19,389          
Beginning Balance at Dec. 31, 2020 32,242 32,496 $ 0 $ 19 458,748 (13) (425,550) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net (loss) income (13,745) (13,745)         (13,745)   0
Unrealized loss on marketable securities (4) (4)       (4)      
Share-based compensation (in shares)       273          
Share-based compensation 683 683     683        
Net proceeds from issuance of common stock and warrants (in shares)       39,860          
Net proceeds from issuances of common stock and warrants 85,479 85,479   $ 41 85,438        
Proceeds from option exercises (in shares)       7          
Proceeds from option exercises 24 24     24        
Ending Balance (shares) at Jun. 30, 2021     10 59,529          
Ending Balance at Jun. 30, 2021 104,679 104,933 $ 0 $ 60 544,893 (17) (439,295) (708) (254)
Beginning Balance (shares) at Mar. 31, 2021     10 59,510          
Beginning Balance at Mar. 31, 2021 110,014 110,268 $ 0 $ 60 544,601 (72) (433,613) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net (loss) income (5,682) (5,682)         (5,682)   0
Unrealized loss on marketable securities 55 55       55      
Share-based compensation (in shares)       0          
Share-based compensation 270 270     270        
Net proceeds from issuance of common stock and warrants (in shares)       19          
Net proceeds from issuances of common stock and warrants 22 22     22        
Ending Balance (shares) at Jun. 30, 2021     10 59,529          
Ending Balance at Jun. 30, 2021 $ 104,679 $ 104,933 $ 0 $ 60 $ 544,893 $ (17) $ (439,295) $ (708) $ (254)